Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in:

Open Access 01-12-2017 | Review

The role of amyloid beta clearance in cerebral amyloid angiopathy: more potential therapeutic targets

Authors: Xue-mei Qi, Jian-fang Ma

Published in: Translational Neurodegeneration | Issue 1/2017

Login to get access

Abstract

Cerebral amyloid angiopathy (CAA) is characterized by the deposition of amyloid β-protein (Aβ) in the leptomeningeal and cortical blood vessels, which is an age-dependent risk factor for intracerebral hemorrhage (ICH), ischemic stroke and contributes to cerebrovascular dysfunction leading to cognitive impairment. However clinical prevention and treatment of the disease is very difficult because of its occult onset and severity of the symptoms. In recent years, many anti-amyloid β immunotherapies have not demonstrated clinical efficacy in subjects with Alzheimer’s disease (AD), and the failure may be due to the deposition of Aβ in the cerebrovascular export pathway resulting in further damage to blood vessels and aggravating CAA. So decreased clearance of Aβ in blood vessels plays a crucial role in the development of CAA and AD, and identification of the molecular pathways involved will provide new targets for treatment. In this review, we mainly describe the mechanisms of Aβ clearance through vessels, especially in terms of some proteins and receptors involved in this process.
Literature
1.
Biffi A, Halpin A, Towfighi A, Gilson A, Busl K, Rost N, et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology. 2010;75:693–8.CrossRefPubMedPubMedCentral
2.
Boyle PA, Yu L, Nag S, Leurgans S, Wilson RS, Bennett DA, et al. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology. 2015;85:1930–6.CrossRefPubMedPubMedCentral
3.
Scolding NJ, Joseph F, Kirby PA, Mazanti I, Gray F, Mikol J, et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain. 2005;128:500–15.CrossRefPubMed
4.
Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm. 2002;109:813–36.CrossRefPubMed
5.
6.
Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci. 2004;24:991–8.CrossRefPubMed
7.
Maki T, Okamoto Y, Carare RO, Hase Y, Hattori Y, Hawkes CA, et al. Phosphodiesterase iii inhibitor promotes drainage of cerebrovascular beta-amyloid. Ann Clin Transpl Neurol. 2014;1:519–33.CrossRef
8.
Bales KR, O'Neill SM, Pozdnyakov N, Pan F, Caouette D, Pi Y, et al. Passive immunotherapy targeting amyloid-beta reduces cerebral amyloid angiopathy and improves vascular reactivity. Brain. 2016;139:563–77.CrossRefPubMed
9.
Saito S, Ihara M. New therapeutic approaches for alzheimer’s disease and cerebral amyloid angiopathy. Frontiers Aging Neuroscience. 2014;6:290.CrossRef
10.
Carpentier M, Robitaille Y, DesGroseillers L, Boileau G, Marcinkiewicz M. Declining expression of neprilysin in alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2002;61:849–56.CrossRefPubMed
11.
Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG. Decreased expression and activity of neprilysin in alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2006;65:1012–21.CrossRefPubMed
12.
13.
Lim CS, Alkon DL. Pkcepsilon promotes hud-mediated neprilysin mrna stability and enhances neprilysin-induced abeta degradation in brain neurons. PLoS One. 2014;9:e97756.CrossRefPubMedPubMedCentral
14.
Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, et al. Global brain delivery of neprilysin gene by intravascular administration of aav vector in mice. Sci Rep. 2013;3:1472.CrossRefPubMedPubMedCentral
15.
Kawakubo T, Mori R, Shirotani K, Iwata N, Asai M. Neprilysin is suppressed by dual-specificity tyrosine-phosphorylation regulated kinase 1a (dyrk1a) in down-syndrome-derived fibroblasts. Biol Pharm Bull. 2017;40:327–33.CrossRefPubMed
16.
Morelli L, Llovera RE, Mathov I, Lue LF, Frangione B, Ghiso J, et al. Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy. J Biol Chem. 2004;279:56004–13.CrossRefPubMed
17.
Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades alzheimer amyloid beta-peptide (a beta); retards a beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem. 2001;276:47863–8.CrossRefPubMed
18.
Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S, et al. Angiotensin-converting enzyme (ace) levels and activity in alzheimer’s disease, and relationship of perivascular ace-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2008;34:181–93.CrossRefPubMed
19.
Domingues-Montanari S, Hernandez-Guillamon M, Fernandez-Cadenas I, Mendioroz M, Boada M, Munuera J, et al. Ace variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. Neurobiol Aging. 2011;32(551):e513–22.
20.
Carrano A, Hoozemans JJ, van der Vies SM, Rozemuller AJ, van Horssen J, de Vries HE. Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal. 2011;15:1167–78.CrossRefPubMed
21.
Do TM, Dodacki A, Alata W, Calon F, Nicolic S, Scherrmann JM, et al. Age-dependent regulation of the blood-brain barrier influx/efflux equilibrium of amyloid-beta peptide in a mouse model of alzheimer’s disease (3xtg-ad). J Alzheimers Dis. 2015;49:287–300.CrossRef
22.
Origlia N, Arancio O, Domenici L, Yan SS. Mapk, beta-amyloid and synaptic dysfunction: the role of rage. Expert Rev. Neurother. 2009;9:1635–45.CrossRefPubMed
23.
Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. Rage mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nature Med. 2003;9:907–13.CrossRefPubMed
24.
Candela P, Gosselet F, Saint-Pol J, Sevin E, Boucau MC, Boulanger E, et al. Apical-to-basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by p-glycoprotein. J Alzheimers Dis. 2010;22:849–59.CrossRefPubMed
25.
Guo YX, He LY, Zhang M, Wang F, Liu F, Peng WX. 1,25-dihydroxyvitamin d3 regulates expression of lrp1 and rage in vitro and in vivo, enhancing abeta1-40 brain-to-blood efflux and peripheral uptake transport. Neuroscience. 2016;322:28–38.CrossRefPubMed
26.
Rocken C, Kientsch-Engel R, Mansfeld S, Stix B, Stubenrauch K, Weigle B, et al. Advanced glycation end products and receptor for advanced glycation end products in aa amyloidosis. Am J Pathol. 2003;162:1213–20.CrossRefPubMedPubMedCentral
27.
Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, et al. A multimodal rage-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of alzheimer disease. J Clin Invest. 2012;122:1377–92.CrossRefPubMedPubMedCentral
28.
Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of ttp488 in patients with mild to moderate alzheimer’s disease. BMC Neurol. 2014;14:12.CrossRefPubMedPubMedCentral
29.
Shinohara M, Sato N, Kurinami H, Takeuchi D, Takeda S, Shimamura M, et al. Reduction of brain beta-amyloid (abeta) by fluvastatin, a hydroxymethylglutaryl-coa reductase inhibitor, through increase in degradation of amyloid precursor protein c-terminal fragments (app-ctfs) and abeta clearance. J Biol Chem. 2010;285:22091–102.CrossRefPubMedPubMedCentral
30.
Do TM, Bedussi B, Chasseigneaux S, Dodacki A, Yapo C, Chacun H, et al. Oatp1a4 and an l-thyroxine-sensitive transporter mediate the mouse blood-brain barrier transport of amyloid-beta peptide. J Alzheimers Dis. 2013;36:555–61.PubMed
31.
Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, et al. Abcg2 is upregulated in alzheimer’s brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for abeta (1-40) peptides. J Neuroradiol. 2009;29:5463–75.
32.
Carrano A, Snkhchyan H, Kooij G, van der Pol S, van Horssen J, Veerhuis R, et al. Atp-binding cassette transporters p-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy. Neurobiol Aging. 2014;35:565–75.CrossRefPubMed
33.
34.
Erickson MA, Banks WA. Blood-brain barrier dysfunction as a cause and consequence of alzheimer’s disease. J Cereb Blood Flow Metab. 2013;33:1500–13.CrossRefPubMedPubMedCentral
35.
Pascale CL, Miller MC, Chiu C, Boylan M, Caralopoulos IN, Gonzalez L, et al. Amyloid-beta transporter expression at the blood-csf barrier is age-dependent. Fluids Barriers CNS. 2011;8:21.CrossRefPubMedPubMedCentral
36.
Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, et al. Clearance systems in the brain-implications for alzheimer disease. Nat Rev. Neurol. 2015;11:457–70.CrossRefPubMedPubMedCentral
37.
Auderset L, Landowski LM, Foa L. Low density lipoprotein receptor related proteins as regulators of neural stem and progenitor cell function. Stem Cells Int. 2016;2016:2108495.CrossRefPubMedPubMedCentral
38.
Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, et al. Modulation of amyloid beta-protein clearance and alzheimer’s disease susceptibility by the ldl receptor-related protein pathway. J Clin Invest. 2000;106:1159–66.CrossRefPubMedPubMedCentral
39.
Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, et al. Srf and myocardin regulate lrp-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol. 2009;11:143–53.CrossRefPubMed
40.
Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein e receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol. 1995;37:211–7.CrossRefPubMed
41.
Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. Apoe isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Investig. 2008;118:4002–13.CrossRefPubMedPubMedCentral
42.
Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, et al. Human apolipoprotein e4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci. 2005;25:2803–10.CrossRefPubMed
43.
Noguchi-Shinohara M, Komatsu J, Samuraki M, Matsunari I, Ikeda T, Sakai K, et al. Cerebral amyloid angiopathy-related microbleeds and cerebrospinal fluid biomarkers in alzheimer’s disease. J Alzheimers Dis. 2017;55(3):905–13.
44.
Hu J, Liu CC, Chen XF, Zhang YW, Xu H, Bu G. Opposing effects of viral mediated brain expression of apolipoprotein e2 (apoe2) and apoe4 on apoe lipidation and abeta metabolism in apoe4-targeted replacement mice. Mol Neurodegener. 2015;10:6.CrossRefPubMedPubMedCentral
45.
Charidimou A, Martinez-Ramirez S, Shoamanesh A, Oliveira-Filho J, Frosch M, Vashkevich A, et al. Cerebral amyloid angiopathy with and without hemorrhage: evidence for different disease phenotypes. Neurology. 2015;84:1206–12.CrossRefPubMedPubMedCentral
46.
Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I. Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor i. J Neuroradiol. 2005;25:10884–93.
47.
Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of alzheimer’s amyloid-ss (1-40) peptide from brain by ldl receptor-related protein-1 at the blood-brain barrier. J Clin Investig. 2000;106:1489–99.CrossRefPubMedPubMedCentral
48.
Dedieu S, Langlois B. Lrp-1: a new modulator of cytoskeleton dynamics and adhesive complex turnover in cancer cells. Cell Adhes Migr. 2008;2:77–80.CrossRef
49.
Kanekiyo T, Bu G. The low-density lipoprotein receptor-related protein 1 and amyloid-beta clearance in alzheimer’s disease. Front Aging Neurosci. 2014;6:93.CrossRefPubMedPubMedCentral
50.
Storck SE, Meister S, Nahrath J, Meissner JN, Schubert N, Di Spiezio A, et al. Endothelial lrp1 transports amyloid-beta1-42 across the blood-brain barrier. J Clin Invest. 2016;126:123–36.CrossRefPubMed
51.
Gonias SL, Campana WM. Ldl receptor-related protein-1: a regulator of inflammation in atherosclerosis, cancer, and injury to the nervous system. Am J Pathol. 2014;184:18–27.CrossRefPubMedPubMedCentral
52.
Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. Lrp/amyloid beta-peptide interaction mediates differential brain efflux of abeta isoforms. Neuron. 2004;43:333–44.CrossRefPubMed
53.
Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human alzheimer’s amyloid beta-peptide and apolipoproteins e and j in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909–18.CrossRefPubMed
54.
Merino-Zamorano C, Fernandez-de Retana S, Montanola A, Batlle A, Saint-Pol J, Mysiorek C, et al. Modulation of amyloid-beta1-40 transport by apoa1 and apoj across an in vitro model of the blood-brain barrier. J Alzheimers Dis. 2016;53:677–91.CrossRefPubMed
55.
Dietrich M, Antequera D, Pascual C, Castro N, Bolos M, Carro E. Alzheimer’s disease-like impaired cognition in endothelial-specific megalin-null mice. J Alzheimers Dis. 2014;39:711–7.PubMed
56.
Ito S, Ueno T, Ohtsuki S, Terasaki T. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (lrp-1) for amyloid-beta peptide (1-40) in mouse: involvement of an lrp-1-independent pathway. J Neurochem. 2010;113:1356–63.PubMed
57.
Shiiki T, Ohtsuki S, Kurihara A, Naganuma H, Nishimura K, Tachikawa M, et al. Brain insulin impairs amyloid-beta (1-40) clearance from the brain. J Neurosci. 2004;24:9632–7.CrossRefPubMed
58.
Ito S, Ohtsuki S, Murata S, Katsukura Y, Suzuki H, Funaki M, et al. Involvement of insulin-degrading enzyme in insulin- and atrial natriuretic peptide-sensitive internalization of amyloid-beta peptide in mouse brain capillary endothelial cells. J Alzheimers Dis. 2014;38:185–200.PubMed
59.
Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: Amyloid beta accumulates in putative interstitial fluid drainage pathways in alzheimer’s disease. Am J Pathol. 1998;153:725–33.CrossRefPubMedPubMedCentral
60.
Wu C, Ivars F, Anderson P, Hallmann R, Vestweber D, Nilsson P, et al. Endothelial basement membrane laminin alpha5 selectively inhibits t lymphocyte extravasation into the brain. Nature Med. 2009;15:519–27.CrossRefPubMed
61.
Hawkes CA, Gatherer M, Sharp MM, Dorr A, Yuen HM, Kalaria R, et al. Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-beta from the mouse brain. Aging Cell. 2013;12:224–36.CrossRefPubMed
62.
Ball KK, Cruz NF, Mrak RE, Dienel GA. Trafficking of glucose, lactate, and amyloid-beta from the inferior colliculus through perivascular routes. J Cereb Blood Flow Metab. 2010;30:162–76.CrossRefPubMed
63.
64.
Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JA, Carare RO. Disruption of arterial perivascular drainage of amyloid-beta from the brains of mice expressing the human apoe epsilon4 allele. PLoS One. 2012;7:e41636.CrossRefPubMedPubMedCentral
65.
Sakai K, Boche D, Carare R, Johnston D, Holmes C, Love S, et al. Abeta immunotherapy for alzheimer’s disease: effects on apoe and cerebral vasculopathy. Acta Neuropathol. 2014;128:777–89.CrossRefPubMed
66.
Rolyan H, Feike AC, Upadhaya AR, Waha A, Van Dooren T, Haass C, et al. Amyloid-beta protein modulates the perivascular clearance of neuronal apolipoprotein e in mouse models of alzheimer’s disease. J Neural Transm. 2011;118:699–712.CrossRefPubMed
67.
Zekonyte J, Sakai K, Nicoll JA, Weller RO, Carare RO. Quantification of molecular interactions between apoe, amyloid-beta (abeta) and laminin: relevance to accumulation of abeta in alzheimer’s disease. Biochim Biophys Acta. 1862;2016:1047–53.
68.
Miyata M, Smith JD. Apolipoprotein e allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nature Genet. 1996;14:55–61.CrossRefPubMed
69.
Craggs L, Taylor J, Slade JY, Chen A, Hagel C, Kuhlenbaeumer G, et al. Clusterin/apolipoprotein j immunoreactivity is associated with white matter damage in cerebral small vessel diseases. Neuropathol Appl Neurobiol. 2016;42:194–209.CrossRefPubMed
70.
Boncoraglio GB, Piazza F, Savoiardo M, Farina L, DiFrancesco JC, Prioni S, et al. Prodromal alzheimer’s disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-abeta autoantibodies. J Alzheimers Dis. 2015;45:363–7.PubMed
71.
Diem AK, Tan M, Bressloff NW, Hawkes C, Morris AW, Weller RO, et al. A simulation model of periarterial clearance of amyloid-beta from the brain. Frontiers Aging Neuroscience. 2016;8:18.CrossRef
72.
Taguchi A, Takata Y, Ihara M, Kasahara Y, Tsuji M, Nishino M, et al. Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis. Psychogeriatrics. 2013;13:164–9.CrossRefPubMed
73.
Hitscherich K, Smith K, Cuoco JA, Ruvolo KE, Mancini JD, Leheste JR, et al. The glymphatic-lymphatic continuum: opportunities for osteopathic manipulative medicine. J Am Optom Assoc. 2016;116:170–7.
74.
Pullen RG, DePasquale M, Cserr HF. Bulk flow of cerebrospinal fluid into brain in response to acute hyperosmolality. Am J Phys. 1987;253:F538–45.
75.
Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA. Evidence for a ‘paravascular’ fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res. 1985;326:47–63.CrossRefPubMed
76.
Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates csf flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012;4:147ra111.CrossRefPubMedPubMedCentral
77.
Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014;76:845–61.CrossRefPubMedPubMedCentral
78.
Xu Z, Xiao N, Chen Y, Huang H, Marshall C, Gao J, et al. Deletion of aquaporin-4 in app/ps1 mice exacerbates brain abeta accumulation and memory deficits. Mol Neurodegener. 2015;10:58.CrossRefPubMedPubMedCentral
79.
Hoshi A, Yamamoto T, Shimizu K, Ugawa Y, Nishizawa M, Takahashi H, et al. Characteristics of aquaporin expression surrounding senile plaques and cerebral amyloid angiopathy in alzheimer disease. J Neuropathol Exp Neurol. 2012;71:750–9.CrossRefPubMed
80.
Zeppenfeld DM, Simon M, Haswell JD, D'Abreo D, Murchison C, Quinn JF, et al. Association of perivascular localization of aquaporin-4 with cognition and alzheimer disease in aging brains. JAMA Neurol. 2017;74:91–9.CrossRefPubMed
81.
Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337–41.CrossRefPubMedPubMedCentral
82.
Saito S, Kojima S, Oishi N, Kakuta R, Maki T, Yasuno F, et al. A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: the comcid study protocol. Alzheimer’s & Dementia: Trans Res Clin Interven. 2016;2:250–7.
83.
Kimura T, Hamazaki TS, Sugaya M, Fukuda S, Chan T, Tamura-Nakano M, et al. Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells. J Dermatol Sci. 2014;74:150–8.CrossRefPubMed
84.
Shen Y, Lue L, Yang L, Roher A, Kuo Y, Strohmeyer R, et al. Complement activation by neurofibrillary tangles in alzheimer’s disease. Neurosci Lett. 2001;305:165–8.CrossRefPubMed
85.
86.
Walker DG, Dalsing-Hernandez JE, Lue LF. Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway: a potential mechanism for vascular damage in cerebral amyloid angiopathy and alzheimer’s disease. Micro Res. 2008;75:411–9.CrossRef
87.
Lian H, Litvinchuk A, Chiang AC, Aithmitti N, Jankowsky JL, Zheng H. Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of alzheimer’s disease. J Neurosci. 2016;36:577–89.CrossRefPubMedPubMedCentral
88.
Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited alzheimer’s mice. Proc Natl Acad Sci U S A. 2002;99:10837–42.CrossRefPubMedPubMedCentral
89.
90.
Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, et al. Peripheral clearance of amyloid beta peptide by complement c3-dependent adherence to erythrocytes. Neurobiol Aging. 2006;27:1733–9.CrossRefPubMed
91.
Lambert JC. Genome-wide association study identifies variants at clu and cr1 associated with alzheimer’s disease. Nat Genet. 2009;41:1094–9.CrossRefPubMed
92.
Chibnik LB, Shulman JM, Leurgans SE, Schneider JA, Wilson RS, Tran D, et al. Cr1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol. 2011;69:560–9.CrossRefPubMedPubMedCentral
93.
Farfel JM, Yu L, Buchman AS, Schneider JA, De Jager PL, Bennett DA. Relation of genomic variants for alzheimer disease dementia to common neuropathologies. Neurology. 2016;87:489–96.CrossRefPubMedPubMedCentral
94.
Biffi A, Shulman JM, Jagiella JM, Cortellini L, Ayres AM, Schwab K, et al. Genetic variation at cr1 increases risk of cerebral amyloid angiopathy. Neurology. 2012;78:334–41.CrossRefPubMedPubMedCentral
95.
Brouwers N, Van Cauwenberghe C, Engelborghs S, Lambert JC, Bettens K, Le Bastard N, et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing c3b/c4b binding sites. Mol Psychiatry. 2012;17:223–33.CrossRefPubMed
96.
Jacquet M, Lacroix M, Ancelet S, Gout E, Gaboriaud C, Thielens NM, et al. Deciphering complement receptor type 1 interactions with recognition proteins of the lectin complement pathway. J Immunol. 2013;190:3721–31.CrossRefPubMed
97.
Larvie M, Shoup T, Chang WC, Chigweshe L, Hartshorn K, White MR, et al. Mannose-binding lectin binds to amyloid beta protein and modulates inflammation. J Biomed Biotechnol. 2012;2012:929803.CrossRefPubMedPubMedCentral
98.
Chen CH, Ghiran I, Beurskens FJ, Weaver G, Vincent JA, Nicholson-Weller A, et al. Antibody cr1-2b11 recognizes a non-polymorphic epitope of human cr1 (cd35). Clin Exp Immunol. 2007;148:546–54.CrossRefPubMedPubMedCentral
99.
Fonseca MI, Chu S, Pierce AL, Brubaker WD, Hauhart RE, Mastroeni D, et al. Analysis of the putative role of cr1 in alzheimer’s disease: genetic association, expression and function. PLoS One. 2016;11:e0149792.CrossRefPubMedPubMedCentral
Metadata
Title
The role of amyloid beta clearance in cerebral amyloid angiopathy: more potential therapeutic targets
Authors
Xue-mei Qi
Jian-fang Ma
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2017
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-017-0091-7

Other articles of this Issue 1/2017

Nicotine from cigarette smoking and diet and Parkinson disease: a review

  • Open Access
  • Review

Mild cognitive impairment in Parkinson’s disease: a distinct clinical entity?

  • Open Access
  • Review

Serial deletion reveals structural basis and stability for the core enzyme activity of human glutaminase 1 isoforms: relevance to excitotoxic neurodegeneration

  • Open Access
  • Research

Quercetin prevents spinal motor neuron degeneration induced by chronic excitotoxic stimulus by a sirtuin 1-dependent mechanism

  • Open Access
  • Research

Endoplasmic reticulum-mitochondria tethering in neurodegenerative diseases

  • Open Access
  • Review

Clinical features of Parkinson’s disease with and without rapid eye movement sleep behavior disorder

  • Open Access
  • Research